Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.02.019
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancer therapy & Oncology International Journal
2017English

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib

Clinical Cancer Research
Cancer ResearchOncology
2016English

Obinutuzumab in Chronic Lymphocytic Leukemia: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

The Impact of Dose Modification and Temporary Interruption of Ibrutinib on Outcomes of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2020English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Real World Outcomes of Obinutuzumab Monotherapy in Patients With Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib

Cancer
Cancer ResearchOncology
2018English

A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: The Combination of Idelalisib and Rituximab

Postdoc journal
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy